05.09.2018
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler AG plans intra-group merger with the Belgian Eckert & Ziegler BEBIG SA
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Merger
Eckert & Ziegler AG plans intra-group merger with the Belgian Eckert &
Ziegler BEBIG SA
05.09.2018 / 19:16
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 5 September 2018. Upon consultation with its Supervisory Board, the
Board of Directors of Berlin-based Eckert & Ziegler (EZAG) has decided today
to advance preparations for a merger of its Belgian subsidiary Eckert &
Ziegler BEBIG SA (EZB) with EZAG. EZAG already holds nearly 81% of the
shares and almost 84% of the voting rights in EZB. The merger plan for the
cross-border merger is currently being compiled by both companies. Within
the scope of these plans, both EZAG and EZB are working on the assumption
that the share conversion ratio will range in the area of one EZAG share at
4.15 to 5.90 EZB shares. Plans call for granting EZB shareholders treasury
shares held by EZAG. A capital increase on the part of EZAG within the scope
of this merger will therefore not be required. Additional details as well as
definitive information regarding the conversion ratio will be announced when
the extraordinary general meeting of shareholders is convened.
The objective of the merger is to streamline the corporate structure of the
EZAG Group as well as the associated regulatory reporting. The merger will
serve to lay the foundation for the successful advancement and continued
profitable growth of the Eckert & Ziegler Group.
The conclusion of the merger in particular is subject to the approval of the
general shareholder meetings of both companies and the granting of
governmental clearances. The intention is to hold the extraordinary general
meetings of EZAG and EZB this year.
"Dual stock exchange listings within the group mean higher administrative
expenditures that are compensated by only minor economic benefits. Ending
the stock exchange listing and the thus associated cost savings, reduces the
annual expenditure of EZB significantly, including the statutory audit of
the annual accounts," explains Dr. Andreas Eckert, CEO of Eckert & Ziegler
AG.
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), which
has over 800 employees, is one of the world's largest providers of isotope
technology for radiotherapy and nuclear medicine.
Contributing to saving lives
Your contact for inquiries:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.de
---------------------------------------------------------------------------
05.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
721029 05.09.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ